{"doi":"10.1016/j.ejim.2024.10.029","title":"Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology","abstract":null,"journal":"European Journal of Internal Medicine","year":2025,"id":609410,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1566338,"name":"Francesca Romana Spinelli","orcid":"0000-0003-1969-2097","position":1,"is_corresponding":false},{"id":1566339,"name":"Gian Luca Erre","orcid":"0000-0001-6818-7666","position":2,"is_corresponding":false},{"id":858733,"name":"Matteo Piga","orcid":"0000-0002-1126-8315","position":3,"is_corresponding":false},{"id":853043,"name":"Garifallia Sakellariou","orcid":"0000-0002-1849-5123","position":4,"is_corresponding":false},{"id":1566340,"name":"Andreina Manfredi","orcid":null,"position":5,"is_corresponding":false},{"id":1213746,"name":"Marco Fornaro","orcid":"0000-0003-1716-7432","position":6,"is_corresponding":false},{"id":1005782,"name":"Ombretta Viapiana","orcid":"0000-0003-1917-5655","position":7,"is_corresponding":false},{"id":1566341,"name":"Simone Perniola","orcid":"0000-0001-6918-4731","position":8,"is_corresponding":false},{"id":1156011,"name":"Elisa Gremese","orcid":"0000-0002-2248-1058","position":9,"is_corresponding":false},{"id":1187607,"name":"Fabiola Atzeni","orcid":"0000-0002-9328-3075","position":10,"is_corresponding":false},{"id":1385713,"name":"Elena Bartoloni","orcid":"0000-0003-4776-2136","position":11,"is_corresponding":false},{"id":593253,"name":"Fabio Cacciapaglia","orcid":"0000-0001-7479-4462","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology","abstract":"BACKGROUND/AIM: Lipid-lowering therapy prescription is low in rheumatoid arthritis (RA) patients, often not achieving lipid threshold target despite treatment. However, evidence derives from small, monocentric cohorts. We assessed adherence to lipid-lowering treatment for primary cardiovascular (CV) prevention in a RA cohort according to international guidelines. METHODS: A cross-sectional analysis of an Italian RA cohort was performed. Disease-related features and traditional CV risk factors were collected. The 10-year CV risk was estimated by Systematic COronary Risk Evaluation 2 (SCORE-2) algorithm. The primary preventive dyslipidaemia strategy was assessed according to 2019 European Society of Cardiology/European Atherosclerosis Society guidelines. RESULTS: 1.133 RA patients (78.2% female, aged 60.6±10.2 years) free from CV events were included. According to SCORE-2, 42.9% of patients were at moderate risk (1-5-%), 33.3% at high risk (5-10%) and 23.7% at very high risk (>10%). In the whole cohort, 12.9% of patients with <5%, 23.6% with 5-10% and 32.3% with >10% risk were on statin, respectively (p<0.001). According to 2019 ESC/EAS guidelines, 51.5% of patients had LDL-c at target. Among patients with LDL-c not at target, 76% were not on lipid-lowering treatment. At multivariate analysis, patients with higher CV risk had significantly lower probability of LDL-c at target. CONCLUSION: In a wide Italian RA cohort, more than 50% of patients had high or very high CV risk. In these, lipid-lowering treatment prescription is suboptimal leading to not achievement of LDL-c target. Physicians should improve lipid screening and primary prevention therapy to reduce CV risk and improve CV comorbidity in RA patients.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39500692","pmcid":null,"openalex_id":"https://openalex.org/W4404086981","authors":[],"funders":[],"total_grants":0,"fwci":0.667,"citation_percentile":0.71959866,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":1}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://www.ejinme.com/article/S0953-6205(24)00449-7/pdf","host_type":"journal"},{"url":"https://www.ejinme.com/article/S0953-6205(24)00449-7/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0953620524004497?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0953620524004497?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejim.2024.10.029","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39500692","host_type":"repository"},{"url":"https://hdl.handle.net/11584/460546","host_type":"repository"},{"url":"https://hdl.handle.net/11380/1388809","host_type":"repository"},{"url":"https://hdl.handle.net/11573/1727706","host_type":"repository"}],"fields_of_study":["Rheumatoid Arthritis Research and Therapies","Lipoproteins and Cardiovascular Health","Spondyloarthritis Studies and Treatments"],"mesh_terms":["Heart Disease Risk Factors","Aged","Hypolipidemic Agents","Arthritis, Rheumatoid","Cardiovascular Diseases","Cross-Sectional Studies","Female","Humans","Italy","Cholesterol, LDL","Male","Middle Aged","Primary Prevention","Risk Factors","Practice Guidelines as Topic","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Guideline Adherence","Dyslipidemias"],"keywords":["Medicine","Rheumatoid arthritis","Cohort","Rheumatology","Internal medicine","Physical therapy","Atherosclerosis","Lipid","Dyslipidaemia","cardiovascular"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T07:35:11.375533Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}